CD8A and neoplasm: The DCs then migrate from the tumor lesion to the nearest SLOs to present processed tumor-associated antigens (TAAs) on major histocompatibility complex class I (MHC I) and/or MHC II molecules to CD8+ and CD4+ T cells, respectively, thereby priming the T cells against neoplasm-specific antigens.